比拉斯汀转换治疗慢性自发性荨麻疹的随机对照试验方案
本研究为多中心、开放标签、非劣效性随机平行对照试验,旨在比较比拉斯汀20 mg与H1抗组胺药剂量加倍在难治性慢性自发性荨麻疹患者中的疗效。计划纳入150例对许可剂量H1抗组胺药无反应的患者,主要终点为干预后5-7天总症状评分均值。
要点
- 难治性CSU患者对许可剂量H1抗组胺药无反应时可考虑转换比拉斯汀20 mg。
- 研究设计为非劣效性试验,对照为H1抗组胺药剂量加倍。
- 主要终点为干预后5-7天总症状评分均值。
核心结论
- 该试验旨在验证比拉斯汀20 mg在难治性CSU患者中的疗效非劣效于H1抗组胺药剂量加倍。
研究设计与样本
- 多中心、开放标签、非劣效性、随机、平行对照研究,在日本15家学术医院开展。
- 计划纳入150例对许可剂量H1抗组胺药无反应的难治性CSU患者,按1:1随机分配。
- 干预措施为H1抗组胺药剂量加倍或转换为比拉斯汀20 mg,给药周期7天。
关键数值与推荐
- 主要终点为干预后5-7天总症状评分均值。
- 次要终点为日本版Epworth嗜睡量表从基线至干预开始后7天的变化,用于评估比拉斯汀20 mg在嗜睡方面的安全性是否优于H1抗组胺药剂量加倍。
临床怎么用
- 为对许可剂量H1抗组胺药无反应的难治性CSU患者转换其他H1抗组胺药提供证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic spontaneous urticaria (CSU) is characterized by the spontaneous appearance of wheals, angioedema, or both for > 6 weeks. Continuous treatment with H1-antihistamines is used as a first-line treatment for CSU. However, H1-antihistamine treatment leads to absence of symptoms in less than 50% of patients with CSU. Although Japanese guidelines for the diagnosis and treatment of urticaria recommend an increase in the H1-antihistamine dose or a switch to other H1-antihistamines, there is no evidence supporting a switch to other H1-antihistamines in patients with refractory CSU who are unresponsive to H1-antihistamines at the licensed dose. METHODS: We will conduct a multicenter, open-label, non-inferiority, randomized, parallel, comparison study to determine if the efficacy of bilastine 20 mg is not inferior to that of a twofold H1-antihistamine dose increase in patients with refractory CSU who are unresponsive to H1-antihistamines at the licensed dose. This study will be performed at 15 academic hospitals in Japan, and the administration period (increasing the H1-antihistamine dose twofold vs. switching to bilastine 20 mg) will be 7 days. Participants (n = 150) will be randomized to either an increased H1-antihistamine dose or a switch to bilastine 20 mg at a 1:1 ratio. The primary endpoint, mean of the total symptom score of 5-7 days after the intervention, will be evaluated. The secondary objective is to determine if the safety of bilastine 20 mg regarding somnolence is superior to that of a twofold dose increase of H1-antihistamines. This will be measured by a change in the Japanese version of the Epworth Sleepiness Scale from baseline to 7 days after starting the intervention. DISCUSSION: This multicenter, open-label, non-inferiority, randomized, parallel, comparison study will be, to our knowledge, the first well-designed clinical study to evaluate the efficacy of a switch to other H1-antihistamines in patients with refractory CSU who are unresponsive to H1-antihistamines at the licensed doses. This trial will provide evidence of the efficacy and safety of bilastine when treatment is switched in patients with refractory CSU who are unresponsive to H1-antihistamines at the licensed dose. TRIAL REGISTRATION: Japan Registry of Clinical Trials (jRCT), jRCTs051180105. Registered on 8 March 2019.
引用
- Fukunaga A, Oda Y, Washio K, et al. Efficacy of switching to bilastine, a histamine H1 receptor antagonist, in patients with chronic spontaneous urticaria (H1-SWITCH): study protocol for a randomized controlled trial. Trials. 2020. PMID: 31906999. doi:10.1186/s13063-019-3878-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。